New antituberculosis drugs: from clinical trial to programmatic use

• 主要な著者: Gina Gualano (著者), Susanna Capone (著者), Alberto Matteelli (著者), Fabrizio Palmieri (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2016-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...